Quarter
Charts

NRC Health

NRC

CIK 0000070487 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$35M
↓-4.6% -$2Mvs FY2024 (Q4)
Operating Income
$5M
↓-51.3% -$5Mvs FY2024 (Q4)
Net Income
$2M
↓-72.6% -$5Mvs FY2024 (Q4)
Gross Profit
$35M
↓-4.6% -$2Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
21/100
  • Profitability
    57ROIC 16.5% (10% = solid, 20%+ = moat)
  • Liquidity
    3Current Ratio 0.55 (above 1.5 = solid)
  • Leverage
    0D/E 5.36 (under 0.5 = conservative)
  • Efficiency
    64Asset Turnover 1.03x (1.0+ = capital-efficient)
  • Growth
    1Revenue YoY -4.6% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin 13.3% · trend -8.1pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project NRC's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

3%

Trailing 3-yr CAGR was -15.9%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$9.81
Total enterprise IV
$220M
Diluted shares
0.02B
Terminal PV
$155M (70% of total)
Year-5 FCF
$18M
YearProjected FCFDiscounted PV
+1$16M$15M
+2$17M$14M
+3$17M$13M
+4$18M$12M
+5$18M$11M
Terminal$249M$155M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$11M
investment in PP&E
Dividends paid (TTM)
$11M
cash returned to holders
Stock buybacks (TTM)
$20M
share count reduction
Stock-based comp (TTM)
$3M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$135M
everything owned
Total liabilities
$121M
everything owed
Stockholders' equity
$14M
shareholder claim
Net debt
$71M
LT debt minus cash

Recent performance · 63 quarters

Revenue↓-4.6% -$2M
$35M
Net Income↓-72.6% -$5M
$2M
Free Cash Flow↑+213.1% +$4M
$6M
Operating Margin↓-12.7pts
13.3%

Drill down

NRC Sankey

See NRC Health's revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

NRC Charts

63 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

NRC Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics